Coronavirus company news summary – BioIQ launches at-home Covid-19 test using single saliva sample – SEHA launches pneumonia-detecting CT scanner

16 June 2020 (Last Updated June 16th, 2020 09:40)

Beckman Coulter has announced the availability of its Access SARS-CoV-2 IgG serological assay in regions that accept the CE mark. The test has already been distributed to over 400 hospitals, clinics and clinical diagnostic laboratories in the US and the company has initiated the distribution to international markets. The company has supplied over 16,000 immunoassay analyzers over the world. It has increased the production capacity to supply over 30 million tests monthly.

BioIQ has launched a home test that combines Covid-19, influenza A and B and a 21 test respiratory panel using a single saliva sample. In partnership with P23 Labs, BioIQ is one of the first companies to be awarded Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for Covid-19 home saliva collection.

Celltrion Group has planned to expand its SARS-CoV-2 diagnostic portfolio in a bid to increase access to Covid-19 testing and limit the spread of the coronavirus around the world. The company has already developed a point-of-care antigen testing kit for Covid-19 with South Korean company BBB, but now plans to distribute a second test, a COVID-19 rapid antibody diagnostic test kit, through an agreement with Humasis, a South Korean in-vitro diagnostic company.

Abu Dhabi Health Services Company (SEHA) has launched a computerised tomography (CT) scan for detecting Covid-19-caused pneumonia. This technology is the first of its kind in the UAE. Emirates News Agency reported that the device is present in the Al Ain Hospital and has helped 3,000 patients. The 16-slice mobile CT scanner can check the occurrence of pneumonia which is a common symptom of Covid-19 coronavirus.